Clinical Trial Update: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on safety and tolerability of SPD503 and psychostimulants in children and adolescents with ADHD; results completed and posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD503

Snippet

Sponsor: Shire | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 2 | Status: COMPLETED | Results posted: 2009-11-26